Preenucleation radiotherapy, uveal melanoma, and competing risks

Archives of Ophthalmology

Volumn 126, Issue 4, 2008, Pages 580-581

  Kivelä, Tero ^a   Kujala, Emma ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; ENUCLEATION; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LETTER; PREOPERATIVE CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE; SEX DIFFERENCE; TREATMENT OUTCOME; UVEA MELANOMA;

EID: 42249108119     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.126.4.581     Document Type: Letter

References (6)

1. Kilic E, Stijnen T, de Jong PT, et al. Reduced melanoma-related mortality in uveal melanoma by preenucleation radiotherapy. Arch Ophthalmol. 2005;123(10):1363-1367.
2. Hawkins BS; Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, IV: ten-year mortality findings and prognostic factors: COMS report number 24. Am J Ophthalmol. 2004;138(6):936-951.
3. Gooley TA, Leisenring W, Crowley J, Storer BE. Why Kaplan-Meier fails and cumulative incidence succeeds when estimating failure probabilities in the presence of competing risks. In: Crowley J, ed. Handbook of Statistics in Clinical Oncology. New York, NY: Marcel Dekker; 2001:513-523.
4. Gray RJ. A class of K-sample tests for comparing cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
5. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651-4659.
6. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.